<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01478971</url>
  </required_header>
  <id_info>
    <org_study_id>AFX01-18</org_study_id>
    <secondary_id>U1111-1150-2575</secondary_id>
    <nct_id>NCT01478971</nct_id>
  </id_info>
  <brief_title>Conversion Study From Epoetin Alfa to Monthly Peginesatide Injection in Patients With Chronic Kidney Disease on Dialysis</brief_title>
  <acronym>DIAMOND</acronym>
  <official_title>A Phase 3b Single-Arm, Conversion Study From Epoetin Alfa to Monthly Peginesatide Injection in Patients With Chronic Kidney Disease on Dialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Affymax</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to understand the effects of a dialysis center switching its
      dialysis patients from using Epoetin alfa to peginesatide injection on hemoglobin levels and
      other parameters.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Monthly Erythropoiesis-Stimulating Agents (ESA) dosing, compared with the longstanding
      practice of dosing three times per week, represents a significant change in anemia treatment
      for dialysis patients. Because of the differences in the processes needed to support monthly
      dosing versus thrice weekly dosing, there is a need to prospectively identify and evaluate
      factors in the dialysis environment during center-level transition of patients from one ESA
      to another.

      AFX01-18 is a Phase 3b open-label, single-arm conversion study that was conducted at 5
      hemodialysis sites in the United States, and enrolled Chronic Kidney Disease (CKD) patients
      receiving outpatient, in-center hemodialysis. The study treatment period was approximately 12
      months in duration. Participants received peginesatide injection for approximately six
      months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Undergoing Conversion to Peginesatide Injection</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peginesatide Dosing</measure>
    <time_frame>Month 6 - 12</time_frame>
    <description>The starting dose, mean dose throughout the study, and mean dose during the last week of treatment of peginesatide.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peginesatide Dose Deviations</measure>
    <time_frame>Months 6 - 12</time_frame>
    <description>Data collected by sponsor of study (Affymax), and sponsor did not provide aggregate summary data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Hemoglobin Levels Greater Than 10 and Less Than or Equal to 11 g/dL</measure>
    <time_frame>Months 1, 2, 3, 4, 5 and 6 of each treatment period</time_frame>
    <description>Percentage of participants with hemoglobin values within the hemoglobin range of 10-11 g/dL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Received at Least One Intravenous Iron Dose</measure>
    <time_frame>12 months</time_frame>
    <description>Participants received iron supplementation during the study to prevent iron deficiency and to maintain iron stores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Received a Whole Blood or Red Blood Cell Transfusion</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">184</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <condition>Anemia</condition>
  <arm_group>
    <arm_group_label>peginesatide injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the first 6 months participants received standard of care treatment with epoetin (the Standard of Care Period [SCP]), followed by a 1-week erythropoiesis-stimulating agent (ESA)-Free Period, followed by peginesatide injection for 6 months (the Peginesatide Treatment Period [PTP]).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epoetin</intervention_name>
    <description>Commercially available epoetin alfa administered weekly, twice weekly, or thrice weekly at an initial starting dose, frequency of administration, and mode of administration (intravenous [IV] or subcutaneous [SC]) individually determined for each participant using the site's usual standard of care. Subsequent dose adjustments or dose holds may have been made in order to maintain a hemoglobin concentration of &lt;11 g/dL.</description>
    <arm_group_label>peginesatide injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peginesatide</intervention_name>
    <description>Administered as a once monthly intravenous (IV) or subcutaneous (SC) injection. The initial dose of peginesatide injection was based on the final weekly dose of epoetin administered in the SCP; subsequent doses may have been adjusted in order to maintain hemoglobin concentrations at &lt;11 g/dL.</description>
    <arm_group_label>peginesatide injection</arm_group_label>
    <other_name>Omontys</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have provided written informed consent in accordance with institutional, local, and
             national guidelines

          -  Are ≥18 years of age at the start of screening

          -  Have been on in-center hemodialysis for ≥12 weeks at the start of screening

          -  Are currently maintained on Epoetin at the start of screening

          -  If sexually active and a female of childbearing potential, are willing to use highly
             effective method of birth control ≥4 weeks before study enrollment and through the
             study

          -  If a female of childbearing potential, have a negative pregnancy test during screening

        Exclusion Criteria:

          -  Are scheduled for a renal transplantation during study (Note: patients awaiting
             transplantation with no date scheduled may enroll.)

          -  Have an active malignancy or malignancy treated within one year prior to the start of
             screening for curative or palliative intent (Note: patients with non-melanoma skin
             cancers may enroll.)

          -  Have known intolerance to any ESA or PEGylated molecule

          -  Have been exposed to any investigational agent during the four weeks prior to the
             start of screening or are anticipated to receive such agents during the study

          -  Have any significant medical or psychiatric condition judged by the investigator to
             prevent informed consent or study compliance

          -  Are pregnant or nursing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director, Clinical Science</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95825</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>91910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>North Brunswick</city>
        <state>New Jersey</state>
        <zip>08902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 22, 2011</study_first_submitted>
  <study_first_submitted_qc>November 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2011</study_first_posted>
  <results_first_submitted>February 6, 2014</results_first_submitted>
  <results_first_submitted_qc>April 29, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 26, 2014</results_first_posted>
  <last_update_submitted>September 16, 2016</last_update_submitted>
  <last_update_submitted_qc>September 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anemia</keyword>
  <keyword>Chronic Renal Failure</keyword>
  <keyword>CRF</keyword>
  <keyword>Chronic Kidney Disease</keyword>
  <keyword>CKD</keyword>
  <keyword>Erythropoietin</keyword>
  <keyword>Hematide</keyword>
  <keyword>Peginesatide</keyword>
  <keyword>Hemoglobin</keyword>
  <keyword>Hgb</keyword>
  <keyword>Red Blood Cell</keyword>
  <keyword>Red Blood Cell Production</keyword>
  <keyword>Dialysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in the study at 5 investigative sites in the United States from 11 October 2011 to 08 February 2013.</recruitment_details>
      <pre_assignment_details>Participants with chronic kidney disease and on dialysis continued to receive their standard of care epoetin treatment for 6 months and then transitioned to receive peginesatide injection for 6 months.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Peginesatide Injection</title>
          <description>In the first 6 months participants received Standard of Care treatment with epoetin (the Standard of Care Period [SCP]), followed by a 1 -week erythropoiesis-stimulating agent (ESA)-free period, followed by a transition to once monthly peginesatide injection for 6 months (the Peginesatide Treatment Period [PTP]).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Standard of Care Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="184"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="178"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="159"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Peginesatide Treatment Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="157">2 participants terminated the study before transitioning to peginesatide for unknown reasons</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="143"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Peginesatide Injection</title>
          <description>In the first 6 months participants received Standard of Care treatment with epoetin (the Standard of Care Period [SCP]), followed by a 1 -week erythropoiesis-stimulating agent (ESA)-free period, followed by a transition to once monthly peginesatide injection for 6 months (the Peginesatide Treatment Period [PTP]).</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="178"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.6" spread="15.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>65 - 74 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 75 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="178" spread="3.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <description>Weight data only available for 177 participants.</description>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83.8" spread="22.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time on dialysis</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.2" spread="3.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Kidney transplant recipient</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Nephrotic syndrome history</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Primary cause of chronic kidney disease</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Diabetes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypertension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cystic renal disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interstitial nephritis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glomerulonephritis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urological</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Immunoglobulin (Ig) A nephropathy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Congenital</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Current dialysis frequency</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>2 times a week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 times a week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 times a week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 times a week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 times a week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline hemoglobin</title>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.9" spread="0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ferritin</title>
          <description>Ferritin data only available for 149 participants.</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1068.7" spread="513.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Transferrin saturation</title>
          <description>Transferrin saturation data only available for 146 participants.</description>
          <units>percent saturation</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.2" spread="13.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Undergoing Conversion to Peginesatide Injection</title>
        <time_frame>6 months</time_frame>
        <population>All participants who received at least one dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Peginesatide Injection</title>
            <description>In the first 6 months participants received Standard of Care treatment with epoetin (the Standard of Care Period [SCP]), followed by a 1 -week erythropoiesis-stimulating agent (ESA)-free period, followed by a transition to once monthly peginesatide injection for 6 months (the Peginesatide Treatment Period [PTP]).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Undergoing Conversion to Peginesatide Injection</title>
          <population>All participants who received at least one dose of study treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="178"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peginesatide Dosing</title>
        <description>The starting dose, mean dose throughout the study, and mean dose during the last week of treatment of peginesatide.</description>
        <time_frame>Month 6 - 12</time_frame>
        <population>Participants who received at least 1 dose of study treatment during the Peginesatide Treatment Period.</population>
        <group_list>
          <group group_id="O1">
            <title>Peginesatide Injection</title>
            <description>In the first 6 months participants received Standard of Care treatment with epoetin (the Standard of Care Period [SCP]), followed by a 1 -week erythropoiesis-stimulating agent (ESA)-free period, followed by a transition to once monthly peginesatide injection for 6 months (the Peginesatide Treatment Period [PTP]).</description>
          </group>
        </group_list>
        <measure>
          <title>Peginesatide Dosing</title>
          <description>The starting dose, mean dose throughout the study, and mean dose during the last week of treatment of peginesatide.</description>
          <population>Participants who received at least 1 dose of study treatment during the Peginesatide Treatment Period.</population>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Starting Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" spread="2.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Average Dose During Treatment Period</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" spread="2.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Last Weekly Average Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" spread="3.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peginesatide Dose Deviations</title>
        <description>Data collected by sponsor of study (Affymax), and sponsor did not provide aggregate summary data.</description>
        <time_frame>Months 6 - 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Peginesatide Injection</title>
            <description>In the first 6 months participants received Standard of Care treatment with epoetin (the Standard of Care Period [SCP]), followed by a 1 -week erythropoiesis-stimulating agent (ESA)-free period, followed by a transition to once monthly peginesatide injection for 6 months (the Peginesatide Treatment Period [PTP]).</description>
          </group>
        </group_list>
        <measure>
          <title>Peginesatide Dose Deviations</title>
          <description>Data collected by sponsor of study (Affymax), and sponsor did not provide aggregate summary data.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Hemoglobin Levels Greater Than 10 and Less Than or Equal to 11 g/dL</title>
        <description>Percentage of participants with hemoglobin values within the hemoglobin range of 10-11 g/dL.</description>
        <time_frame>Months 1, 2, 3, 4, 5 and 6 of each treatment period</time_frame>
        <population>Full Analysis Population included all enrolled participants who received at least 1 dose of study treatment during the Peginesatide Treatment Period. n indicates the number of participants with available data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Epoetin Standard of Care</title>
            <description>In the first 6 months participants received Standard of Care treatment with epoetin (the Standard of Care Period [SCP]).</description>
          </group>
          <group group_id="O2">
            <title>Peginesatide Treatment Period</title>
            <description>In the second six months of the study participants transitioned to peginesatide injection (the Peginesatide Treatment Period [PTP]).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Hemoglobin Levels Greater Than 10 and Less Than or Equal to 11 g/dL</title>
          <description>Percentage of participants with hemoglobin values within the hemoglobin range of 10-11 g/dL.</description>
          <population>Full Analysis Population included all enrolled participants who received at least 1 dose of study treatment during the Peginesatide Treatment Period. n indicates the number of participants with available data at each time point.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
                <count group_id="O2" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 1 (n=156, 155)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.1"/>
                    <measurement group_id="O2" value="44.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2 (n=157, 155)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.8"/>
                    <measurement group_id="O2" value="46.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 (n=156, 155)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.0"/>
                    <measurement group_id="O2" value="45.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 4 (n=156, 151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.9"/>
                    <measurement group_id="O2" value="49.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 5 (n=157, 147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.7"/>
                    <measurement group_id="O2" value="44.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month6 (n=157, 146)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.0"/>
                    <measurement group_id="O2" value="39.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Received at Least One Intravenous Iron Dose</title>
        <description>Participants received iron supplementation during the study to prevent iron deficiency and to maintain iron stores.</description>
        <time_frame>12 months</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Epoetin Standard of Care</title>
            <description>In the first 6 months participants received Standard of Care treatment with epoetin (the Standard of Care Period [SCP]).</description>
          </group>
          <group group_id="O2">
            <title>Peginesatide Treatment Period</title>
            <description>In the second six months of the study participants transitioned to peginesatide injection (the Peginesatide Treatment Period [PTP]).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Received at Least One Intravenous Iron Dose</title>
          <description>Participants received iron supplementation during the study to prevent iron deficiency and to maintain iron stores.</description>
          <population>Safety population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="178"/>
                <count group_id="O2" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.4"/>
                    <measurement group_id="O2" value="73.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Received a Whole Blood or Red Blood Cell Transfusion</title>
        <time_frame>12 months</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Epoetin Standard of Care</title>
            <description>In the first 6 months participants received Standard of Care treatment with epoetin (the Standard of Care Period [SCP]).</description>
          </group>
          <group group_id="O2">
            <title>Peginesatide Treatment Period</title>
            <description>In the second six months of the study participants transitioned to peginesatide injection (the Peginesatide Treatment Period [PTP]).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Received a Whole Blood or Red Blood Cell Transfusion</title>
          <population>Safety population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="178"/>
                <count group_id="O2" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.7"/>
                    <measurement group_id="O2" value="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 months plus 4 to 5 weeks after the last dose of study treatment or last visit.</time_frame>
      <desc>At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Epoetin Standard of Care</title>
          <description>In the first 6 months participants received Standard of Care treatment with epoetin (the Standard of Care Period [SCP]).</description>
        </group>
        <group group_id="E2">
          <title>ESA Free Week</title>
          <description>A one-week erythropoiesis-stimulating agent (ESA)-free period following 6 months of standard of care.</description>
        </group>
        <group group_id="E3">
          <title>Peginesatide Treatment Period</title>
          <description>In the second six months of the study participants transitioned to once monthly peginesatide injection (the Peginesatide Treatment Period [PTP]).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="54" subjects_at_risk="157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Haemorrhagic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Nodal rhythm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Diabetic gastroparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Gastric antral vascular ectasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Impaired gastric emptying</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Oesophageal achalasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Device malfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Systemic inflammatory response syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Face oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Generalised oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Bile duct obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula site infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Device related sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Infectious peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Cholangitis suppurative</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Empyema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Enterococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Enterococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Klebsiella sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Lung abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Peritonitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Pneumonia klebsiella</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Urinary tract infection enterococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Arthritis infective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula site complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Vascular graft complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Vascular graft thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Troponin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Hypoglycaemic seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Spinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Costochondritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Diffuse large B-cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Endometrial cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Gallbladder cancer stage II</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Laryngeal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma stage III</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Grand mal convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Hepatic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Myoclonus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Cerebellar infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Toxic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Lung infiltration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dry gangrene</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Raynaud's phenomenon</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Brachiocephalic vein stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="157"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="74" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="70" subjects_at_risk="157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula site complication</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperphosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="178"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="157"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Takeda</organization>
      <phone>800-778-2860</phone>
      <email>clinicaltrialregistry@tpna.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

